<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/027565E4-50E9-45A7-B48D-D81688C836CF"><gtr:id>027565E4-50E9-45A7-B48D-D81688C836CF</gtr:id><gtr:name>WaVe Biosciences</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A9426E3-7F35-48FC-BD72-3776C8F90A4A"><gtr:id>4A9426E3-7F35-48FC-BD72-3776C8F90A4A</gtr:id><gtr:name>Grants Admin Office</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/027565E4-50E9-45A7-B48D-D81688C836CF"><gtr:id>027565E4-50E9-45A7-B48D-D81688C836CF</gtr:id><gtr:name>WaVe Biosciences</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A9426E3-7F35-48FC-BD72-3776C8F90A4A"><gtr:id>4A9426E3-7F35-48FC-BD72-3776C8F90A4A</gtr:id><gtr:name>Grants Admin Office</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/ACD6437C-C203-4D72-B0AF-9A502AB5C3BF"><gtr:id>ACD6437C-C203-4D72-B0AF-9A502AB5C3BF</gtr:id><gtr:firstName>William</gtr:firstName><gtr:otherNames>Henry</gtr:otherNames><gtr:surname>McLean</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C62A660D-A97B-447A-B072-F5D38B942F07"><gtr:id>C62A660D-A97B-447A-B072-F5D38B942F07</gtr:id><gtr:firstName>Nicholas James</gtr:firstName><gtr:surname>Westwood</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6E5DC5FB-4C63-45E1-B18C-926E2F5F26C3"><gtr:id>6E5DC5FB-4C63-45E1-B18C-926E2F5F26C3</gtr:id><gtr:firstName>Julie</gtr:firstName><gtr:surname>Frearson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700314"><gtr:id>141DE7F5-ADFB-4B3F-AA22-02AA4794F8BC</gtr:id><gtr:title>In vivo model systems to develop filaggrin as a drug target in atopic disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700314</gtr:grantReference><gtr:abstractText>We recently discovered the major gene that causes eczema and a host of other conditions associated with eczema, such as allergies and eczema-associated asthma. The filaggrin gene, which makes a protein essential for skin barrier formation, is completely deactivated by genetic mutations in about 10% of the population, leading to ?leaky? skin that allows foreign material such as bacteria, allergens and chemicals to enter the body. These foreign substances are seen by the immune system and this leads to inflammation of the skin (eczema) and as a secondary event, other systems such as the lungs (asthma). The filaggrin gene is an ideal target for two different types of drugs that can eithr rescue certain defective genes and switch them back on again, or boost the activity of a gene. We have shown that these drugs can indeed rescue or boost filaggrin production in cells and skin. This grant is designed to develop animal models that closely mimic the human filaggrin defects. This will allow us to dissect out the disease mechanisms and importantly, to test the new therapy systems aimed at this gene. This project has the potential to treat over 4 million people in the UK, or 10s of millions worldwide. If administered early, such drugs could prevent the onset of eczema and associated diseases, such as allergies and certain types of asthma and hay fever.</gtr:abstractText><gtr:technicalSummary>We recently discovered that loss-of-function mutations in the filaggrin gene cause atopic dermatitis (eczema) and a host of other associated atopic conditions, such as allergies and eczema-associated asthma. Filaggrin is essential for skin barrier formation and is deactivated by genetic mutations in about 10% of the population, leading to permeable skin that allows antigens, allergens and chemicals to enter the body, leading to inflammation of the skin (eczema) and other organ systems (allergies and asthma). The filaggrin gene is the best target yet discovered for drugs such as gentamicin, negamycin and others that can rescue premature termination codon (nonsense) mutations by binding to the 16S ribosome subunit and allowing the ribosome to read-through the mutant stop codon. We have shown that this class of drug an indeed rescue filaggrin production in cultured cells and skin from filaggrin-null patients. A medicinal chemistry component, in house at nearby St Andrews University, is aimed at developing one new type of low toxicity, highly efficacious readthrough compound, negamycin, for testing in cell culture and animal models of filaggrin-null atopy. We have also shown that another class of small molecules, PPAR-gamma agonists, many of which there are known, are able to increase expression of the filaggrin gene in cultured cells. Since most individuals with filaggrin-related atopy are heterozygous carriers of null-mutations, these drugs might be used to boost expression of the normal allele to therapeutic effect. Mouse models of increasing complexity and similarity to the human disease will be developed for testing both read-through and filaggrin-boosting drugs in vivo using both reporter gene and humanized phenotypic readouts. This project has the potential to find new drugs aimed at treating about 4 million people in the UK, or several 10s of millions worldwide. If administered early, such drugs could prevent the onset of eczema and atopic diseases.</gtr:technicalSummary><gtr:fund><gtr:end>2010-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1012069</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>WaVe Biosciences</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>WaVe</gtr:description><gtr:id>F0EE4057-7E17-4CA6-B08D-C07B68BBD317</gtr:id><gtr:impact>None as yet.</gtr:impact><gtr:outcomeId>5462462487a4a8.07665054-1</gtr:outcomeId><gtr:partnerContribution>None as yet but we anticipate obtaining &amp;quot;stereopure&amp;quot; oligonucleotides for testing in 2015.</gtr:partnerContribution><gtr:piContribution>We established an informal collaboration with WaVe Biosciences in 2014 to test their proprietary &amp;quot;stereopure&amp;quot; antisense oligonucleotides using in vitro and in vivo model systems we have available.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Trinity College Dublin</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:description>Mouse skin barrier immunology</gtr:description><gtr:id>AA321A3E-2390-4A2E-AF9B-C93D1CA8197C</gtr:id><gtr:impact>This study led to the following high-impact paper: Fallon PG, Sasaki T, Sandilands A, Campbell LE, Saunders SP, Mangan NE, Callanan JJ, Kawasaki H, Shiohama A, Kubo A, Sundberg J, Presland RB, Fleckman P, Shimizu N, Kudoh J, Irvine AD, Amagai M and McLean WHI (2008) A homozygous frameshift mutation in the murine filaggrin gene facilitates enhanced percutaneous allergen priming. Nat Genetics 41: 602-608 [Epub ahead of print 6th April 2009].</gtr:impact><gtr:outcomeId>7EC6AE51273-1</gtr:outcomeId><gtr:partnerContribution>This year, we published the first mouse model of eczema based on a mutation in the filaggrin gene (Fallon et al., Nature Genetics, 41: 602-608, 2009). We were the first to do this despite fierce international competition from the two groups in the USA, another in Germany and another in Japan. My partners at Trinity College Dublin, Prof Alan Irvine and in particular, Prof Padraic Fallon, have been instrumental in the immunological characterisation of filaggrin-deficient mice generated in the course of this MRC grant. Prof Fallon performed a number of key experiments without which we would not have been able to get this important work into print ahead of the rest of the world.</gtr:partnerContribution><gtr:piContribution>We developed the flaky tail mouse mutant as a model of filaggrin-related eczema by devising methods to sequence the mouse filaggrin gene for the first time and identifying the 5303delA loss-of-function mutation, equivalent to many simialr mutations found in human patients with ichthyosis vulgaris and/or eczema. This allowed back-crossing of the mutation onto different mouse strains, permitting properly controlled experiments of skin barrier using these mice.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>The Roslin Institute</gtr:department><gtr:description>Roslin</gtr:description><gtr:id>C4474C5B-D3B8-4D0F-953E-8B3DE0C74AE3</gtr:id><gtr:impact>This collaboration is helping us optimise an ex vivo skin culture system. No final outcome yet.</gtr:impact><gtr:outcomeId>56e06b9e5fe6d9.72710482-1</gtr:outcomeId><gtr:partnerContribution>Provision of discarded pig skin following ova harvesting.</gtr:partnerContribution><gtr:piContribution>Developing systems for ex vivo culture of skin.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Progress Educational Trust, London</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>84048CB4-515F-4526-92FB-71CD9FC97AA9</gtr:id><gtr:impact>Prof McLean presented the filaggrin-eczema-ichthyosis story and participated in a panel discussion. This included presenting the mouse model generated in this grant, as well as preliminary data showing that filaggrin therapy is feasible, another output of this grant. The audience consisted of healthcare professionals, educators, social scientists, lay people, policymakers and media.

As a consequence of this meeting, I have been invited to participate in a TV production aimed at secondary school education (led by Nowgen - a Centre for Genetics in Healthcare, a not-for-profit organisation which is affiliated to the Central Manchester NHS Trust and The University of Manchester. Nowgen is funded by the Wellcome Trust to run a 3 year Schools Genomics Programme, which aims to influence the way that genetics is taught in schools.) In addition, I have been asked for and have provided slides from my presentation to number of genetics and other healthcare educators for inclusion in a variety of courses. I had a lengthy conversation with a science journalist from the Sunday Times about the role of skin barrier in eczema and allergy.</gtr:impact><gtr:outcomeId>491B7729958</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>7740203C-6578-4C54-9559-895E0F257859</gtr:id><gtr:impact>65 people attended the public lecture.

Invited to do a follow-up lecture in 2014</gtr:impact><gtr:outcomeId>eTWDJoTjiad</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.cafesciencedundee.co.uk/?p=1235</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Talk, South West Scotland</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>989FF611-6452-4B77-8972-A38449D617C7</gtr:id><gtr:impact>By direct invitation, a 45 min presentation was given to about 100 members of the public involved in fund-raising for skin disease charities, particularly relating to the filaggrin gene in ichthyosis, common dry skin and eczema/allergy, as well as outlining our efforts to develop therapies based on this gene. Lengthy discussion followed - about 15 min formal and 2 hours informal.

Small financial donation to the lab was received from this group.</gtr:impact><gtr:outcomeId>PptJmqDtHM7</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release about Pfizer Collaboration</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5D2E8F84-2335-4459-A234-7F20EE2C946E</gtr:id><gtr:impact>Press release on establishing new research partnership with Pfizer to develop read-through drugs to treat cystic fibrosis and a range of other genetic diseases:
http://www.dundee.ac.uk/research/main/news/20150206091048/978.html
National and international press coverage; local radio interviews</gtr:impact><gtr:outcomeId>56e09c790f68e7.72731646</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.dundee.ac.uk/research/main/news/20150206091048/978.html</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release, Wellcome Trust Strategic Award to Dundee Dermatology and Genetic Medicine</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5C3B9617-5E75-4E83-932A-A2DC2FC98D8F</gtr:id><gtr:impact>Media interviews about the Wellcome Trust's major funding boost for dermatology research at the University of Dundee
e.g. http://www.bbc.co.uk/news/uk-scotland-tayside-central-18883942</gtr:impact><gtr:outcomeId>56e09ad5b22515.18412400</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>DEBRA UK research leadership visit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2199870C-E094-40CB-BCD0-41283FA3501E</gtr:id><gtr:impact>Visits from DEBRA UK Research Managers and lead fundraisers to laboratories, with updates on current research and future planning.</gtr:impact><gtr:outcomeId>56e075f1673419.54859844</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Open Doors Day, College of Life Sciences, Dundee</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>98BFE377-EB4A-4E56-BFB0-5A6072F06447</gtr:id><gtr:impact>Attended College of Life Sciences Open Doors Day where scientists explain their research to a few hundred members of the general public.</gtr:impact><gtr:outcomeId>56e0995248d782.31186861</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release, drug discovery aimed at filaggrin</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0437C9F4-057E-4FFE-A9D0-1D3B3E40AE8F</gtr:id><gtr:impact>Media interviews regarding funding for drug discovery in relation to the filaggrin gene
e.g. http://news.bbc.co.uk/1/hi/scotland/tayside_and_central/7014517.stm</gtr:impact><gtr:outcomeId>56e09823a18e69.15187807</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Lecture (British Association for the Advancement of Science)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B34ADB95-AA31-4627-9128-D1A8D26B7F32</gtr:id><gtr:impact>&amp;quot;Are you thick skinned enough? Dermatology Discoveries in Dundee&amp;quot;. Audience of about 60 people, all from the Tayside region general public. 60 min lecture plus 30 min discussion.</gtr:impact><gtr:outcomeId>58ca532c002c50.93936941</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release regarding Buchanan Medal</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>52F407E2-BDE4-4319-B2AA-80D74F013F73</gtr:id><gtr:impact>Press release on Buchannan Medal of the Royal Society, local and national press coverage
http://www.dundee.ac.uk/news/2015/professor-irwin-mclean-awarded-buchanan-medal-by-royal-society.php</gtr:impact><gtr:outcomeId>56e09d531d4136.70481615</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.dundee.ac.uk/news/2015/professor-irwin-mclean-awarded-buchanan-medal-by-royal-society.php</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release, filaggrin mutant mouse</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>413F68DE-0E83-4686-BD50-29EC9EFC4B6B</gtr:id><gtr:impact>Media interviews regarding the discovery of the filaggrin mutant mouse model of eczema
e.g. http://news.bbc.co.uk/1/hi/scotland/tayside_and_central/7985307.stm</gtr:impact><gtr:outcomeId>56e09877da72e0.47472685</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release about election to The Royal Society</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3DBD16B9-7245-49CF-B500-4FD6A24B6F7B</gtr:id><gtr:impact>Press release about election to The Royal Society:
http://www.dundee.ac.uk/news/2014/professor-irwin-mclean-elected-to-royal-society.php
Several press articles and local radio coverage</gtr:impact><gtr:outcomeId>56e09c061d7581.65714354</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.dundee.ac.uk/news/2014/professor-irwin-mclean-elected-to-royal-society.php</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Undergraduate Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>39CD7C8F-CA38-46FE-8B28-BA5944C519AA</gtr:id><gtr:impact>Undergraduate Open Day, School of Life Sciences</gtr:impact><gtr:outcomeId>56e09ccd04fdf9.46600633</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release about discovery of 10 eczema genes</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9182E464-C39F-4913-B29D-617DC9F1D060</gtr:id><gtr:impact>Press release on identification of 10 new eczema genes; local and national press coverage; local radio interviews; international web coverage
www.dundee.ac.uk/research/main/news/20151020115352/1006.html</gtr:impact><gtr:outcomeId>56e09ddd77b663.68556971</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.dundee.ac.uk/research/main/news/20151020115352/1006.html</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release, filaggrin is a major gene in peanut allergy</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F97B622B-D4AD-41E6-9144-DC15B0DAFCEE</gtr:id><gtr:impact>Media interviews regarding the discovery of the major gene defect underlying peanut allergy
e.g. http://www.bbc.co.uk/news/uk-scotland-tayside-central-12698727</gtr:impact><gtr:outcomeId>56e098ec7ea3e2.96885736</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Lecture, Comber Rotary Club, County Down, Northern Ireland.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>743D7403-1209-4166-82A7-CB0B4F4B88BF</gtr:id><gtr:impact>Public talk hosted by a Rotary Club. &amp;quot;Studying inherited skin disease through thick and thin&amp;quot;. Audience of about 30-40 Rotarians and interested public. 30 min lecture plus 15 min discussion.</gtr:impact><gtr:outcomeId>58ca53aa4596e9.18151263</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>DEBRA Annual Conference, Weybridge, UK</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7449A517-E738-42F9-AC74-E2B079DAF90C</gtr:id><gtr:impact>More than 100 patients with the inherited skin blistering disorder epidermolysis bullosa simplex (EBS) attended 1-day meetings in Weybridge, South of England, and Staffordshire, South of England, to learn about the molecular basis of their disease and hear about progress being made in therapy development.

Owing to the success of this meeting and the preceding one in Scotland, a follow-up meeting was organised to spread this information to patients in the north of England in November 2012. These EBS patient meetings will now be an annual event.</gtr:impact><gtr:outcomeId>abXx2nqxai5</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2012,2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>260000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Discovery Partnerships with Academia</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>GlaxoSmithKline (GSK)</gtr:fundingOrg><gtr:fundingRef>DPAc 440</gtr:fundingRef><gtr:id>D5028552-357E-401B-AA6D-E37FEBA8193C</gtr:id><gtr:outcomeId>NaH8sFFDRF8</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2011-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5869875</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Strategic Award</gtr:description><gtr:end>2017-07-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>098439/Z/12/Z</gtr:fundingRef><gtr:id>9F0536F5-9CFF-4430-9205-B7F01056D2CF</gtr:id><gtr:outcomeId>EM3dAdx9hp9</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>81000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>British Skin Foundation</gtr:fundingOrg><gtr:id>50EFE341-43E3-4E08-8D18-7158E1CA4AEE</gtr:id><gtr:outcomeId>56e071036b9678.10283937</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>Unknown</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Industrial collaboration</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Wave Life Sciences</gtr:fundingOrg><gtr:id>8D7C3D72-6F57-47CD-B5C5-290D60E52FE6</gtr:id><gtr:outcomeId>56e06ec68de0a8.55020798</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Developmental Pathway Funding Scheme (DPFS; Dundee portfolio)</gtr:description><gtr:end>2011-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>2671F496-392B-4A78-93DD-86AF5801712F</gtr:id><gtr:outcomeId>268A4DA6C460</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1565511</gtr:amountPounds><gtr:country>Unknown</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Pfizer Rare Diseases Consortium</gtr:department><gtr:description>Industrial collaboration</gtr:description><gtr:end>2017-01-02</gtr:end><gtr:fundingOrg>Pfizer Ltd</gtr:fundingOrg><gtr:id>924BA438-FE51-4903-B43A-E973E77AD38D</gtr:id><gtr:outcomeId>56e06d8ed715b7.15497381</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2015-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Clinical reviews</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>86BAE99E-D4B9-4480-8EBA-DDFA9021201F</gtr:id><gtr:outcomeId>7024380F19F</gtr:outcomeId><gtr:type>Citation in clinical reviews</gtr:type><gtr:url>http://europepmc.org/abstract/MED/19589816</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Clinical impact of filaggrin research in dermatology</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>9A35E5BA-2A4F-40A1-938F-F60CC774E351</gtr:id><gtr:outcomeId>B32F8B67B7C</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://www.dermquest.com</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>European Dermatology Forum</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>39D480CB-0632-4224-9BFB-A7AAA367E6FC</gtr:id><gtr:outcomeId>kQ4poKLqTSv</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A transgenic mouse was generated whereby a firefly luciferase reporter gene is expressed under control of the human filaggrin promoter.</gtr:description><gtr:id>CEA27A66-72FB-4178-8DAF-52B24840D1BA</gtr:id><gtr:impact>This is the first reporter gene mouse for the filaggrin gene, allowing the in vivo assay of filaggrin expression levels. This has immediate applications in determining efficacy of small molecules aimed at up-regulation of filaggrin expression for therapy in ichthyosis vulgaris, xerosis (dry skin) and atopic eczema/allergy involving genetically determined filaggrin deficiency.

In addition, these mice are a valuable tool for assay of the efficacy and cutaneous delivery of gene silencing agents such as siRNA or antisense RNA applied to skin disease. They are already finding use in two of our other MRC funded projects (MRC Milstein Award G0801742; and MRC Programme grant G0802780), adding value to these grants.</gtr:impact><gtr:outcomeId>ncL9ySBAKhR</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Filaggrin reporter gene mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Following assay development and optimisation, a high-throughput screen of a small molecule library was performed, which led to identification of a number of hit series capable of reading through nonsense mutations in genes causing a wide range of genetic disease, including filaggrin deficiency. The current lead molecule following several rounds of medicinal chemistry is ~500 times more potent than the gold standard readthrough agent geneticin, but importantly is non-toxic and has good in vivo pharmacokinetic properties.</gtr:description><gtr:id>9901FD4D-1720-4716-A78B-8088305A2995</gtr:id><gtr:impact>No public impacts at this stage due to IP issues.</gtr:impact><gtr:outcomeId>LY7nUJ3vMqo</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Small molecules to read through nonsense mutations</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Following cell-based reporter assay development and optimisiation, a high throughput screen of a small molecule library was performed which identified hit series which upregulate human filaggrin expression. The lead series has been confirmed to upregulate filaggrin expressin at the mRNA and protein level in a variety of primary cell systems. These molecules have potential for development into drugs to treat atopic eczema and other filaggrin-related disorders, as well as representing a new tool to study filaggrin gene regulation.</gtr:description><gtr:id>2A8F0103-F10E-485A-9878-BA61B43CF7AF</gtr:id><gtr:impact>No public impacts yet due to IP issues.</gtr:impact><gtr:outcomeId>jsZEHKgRVg5</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Small molecules to upregulate filaggrin expression</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>An existing mouse strain with multiple mutations, known as matted-flaky tail (maft), was characterised as part of this project grant. The filaggrin gene was fully sequenced for the first time (the mouse genome data for filaggrin is incomplete) in this mouse and the 5303delA loss-of-function mutation identified. Genotyping assays for this mutation allowed removal of additional mutations in the maft mouse by backcrossing to obtain a &amp;quot;pure&amp;quot; filaggrin-deficient mutant mouse congenic on C57BL/6. This then facilitates properly controlled studies of homozygous, heterozygous filaggrin mutant mice versus wildtype littermates on a pure congenic mouse background. We are currently backcrossing the mutation onto other mouse strains, which may lead to variations in the phenotypes observed. These mice exhibit a skin barrier deficiency leading to abnormal transcutaneous antigen priming. These mice bear the immunological hallmarks of human atopic eczema - e.g elevated biomarkers such as Th2 cytokines.</gtr:description><gtr:id>866EEFA8-3FEA-4F60-9E02-0440F63B56B2</gtr:id><gtr:impact>First description of filaggrin mutant mice and first experimental evidence that filaggrin deficiency leads to cutaneous antigen/allergen priming: Fallon PG, Sasaki T, Sandilands A, Campbell LE, Saunders SP, Mangan NE, Callanan JJ, Kawasaki H, Shiohama A, Kubo A, Sundberg J, Presland RB, Fleckman P, Shimizu N, Kudoh J, Irvine AD, Amagai M* and McLean WHI* (2009) A homozygous frameshift mutation in the murine filaggrin gene facilitates enhanced percutaneous allergen priming. Nat Genetics 41: 602-608 [Epub ahead of print 6th April 2009].</gtr:impact><gtr:outcomeId>3B1F66DBDF6</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Filaggrin mutant mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>293D27C7-07C4-4566-8154-252557D272F3</gtr:id><gtr:title>Disorders of keratinisation: from rare to common genetic diseases of skin and other epithelial tissues.</gtr:title><gtr:parentPublicationTitle>The Ulster medical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a06ac4c15fa5ab9d9f15bd95c259659"><gtr:id>1a06ac4c15fa5ab9d9f15bd95c259659</gtr:id><gtr:otherNames>McLean WH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0041-6193</gtr:issn><gtr:outcomeId>03F85FF7392</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1166E31-A41C-4C54-B63D-578A2366B22D</gtr:id><gtr:title>FLG mutation p.Lys4021X in the C-terminal imperfect filaggrin repeat in Japanese patients with atopic eczema.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c1ce6f0ed6d5e200e9f2d74e47f7d482"><gtr:id>c1ce6f0ed6d5e200e9f2d74e47f7d482</gtr:id><gtr:otherNames>Nemoto-Hasebe I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>66941ABC52B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6EF62D49-F255-48A9-86F4-CE7E28F7349A</gtr:id><gtr:title>Filaggrin-null mutations are associated with increased maturation markers on Langerhans cells.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74f51c06ed7f09006c98feeccc7e48a5"><gtr:id>74f51c06ed7f09006c98feeccc7e48a5</gtr:id><gtr:otherNames>Leitch CS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>58ca50ae950de8.11122338</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E6FC527-48F7-4B50-B325-096F3C15DBF9</gtr:id><gtr:title>Loss-of-function mutations in the gene encoding filaggrin underlie a Japanese family with food-dependent exercise-induced anaphylaxis.</gtr:title><gtr:parentPublicationTitle>Journal of the European Academy of Dermatology and Venereology : JEADV</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72ad5699b07ba93e9585025a7a431387"><gtr:id>72ad5699b07ba93e9585025a7a431387</gtr:id><gtr:otherNames>Mizuno O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0926-9959</gtr:issn><gtr:outcomeId>56e0681e8e7495.45833705</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CB924C8-3B2D-41AF-99ED-7EE8C31CFEA9</gtr:id><gtr:title>Impact of atopic dermatitis and loss-of-function mutations in the filaggrin gene on the development of occupational irritant contact dermatitis.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6eac5775e4b7c1daea755c6a16a68ab"><gtr:id>f6eac5775e4b7c1daea755c6a16a68ab</gtr:id><gtr:otherNames>Visser MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>pm_15081_21_23039796</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9873B2F-B3A7-45E9-A67C-B72CBF3D537D</gtr:id><gtr:title>Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0f6cee6e470ed40c446ff0e9f5a3149"><gtr:id>d0f6cee6e470ed40c446ff0e9f5a3149</gtr:id><gtr:otherNames>Brown SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>81ABFEBB_881ABFEBB_8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B57F9E72-F543-43A5-A107-88FB6D80CE6F</gtr:id><gtr:title>Missing C-terminal filaggrin expression, NFkappaB activation and hyperproliferation identify the dog as a putative model to study epidermal dysfunction in atopic dermatitis.</gtr:title><gtr:parentPublicationTitle>Experimental dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/653ec4cfa319dd8de5d15c2b77cea453"><gtr:id>653ec4cfa319dd8de5d15c2b77cea453</gtr:id><gtr:otherNames>Chervet L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0906-6705</gtr:issn><gtr:outcomeId>ndyEwKehyUh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D4BED27-C807-43A1-ADB4-7DEA20308D23</gtr:id><gtr:title>A genome-wide association study of atopic dermatitis identifies loci with overlapping effects on asthma and psoriasis.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9667662b8ddb576cb53a1eba36b681b"><gtr:id>a9667662b8ddb576cb53a1eba36b681b</gtr:id><gtr:otherNames>Weidinger S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_15081_21_23886662</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7EC2A13-DC30-4A2D-B380-5D51E1CDA0AE</gtr:id><gtr:title>Skin microbiome before development of atopic dermatitis: Early colonization with commensal staphylococci at 2&amp;nbsp;months is associated with a lower risk of atopic dermatitis at 1&amp;nbsp;year.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/873c137f207bfad9792fbcddb479b6ab"><gtr:id>873c137f207bfad9792fbcddb479b6ab</gtr:id><gtr:otherNames>Kennedy EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>58ca50af5e7d49.90060290</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58ECB14D-751C-4897-8A36-4CFBD759DC23</gtr:id><gtr:title>Clinical severity correlates with impaired barrier in filaggrin-related eczema.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c1ce6f0ed6d5e200e9f2d74e47f7d482"><gtr:id>c1ce6f0ed6d5e200e9f2d74e47f7d482</gtr:id><gtr:otherNames>Nemoto-Hasebe I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>AAD7360621A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>974255FD-1C8B-4894-BCD6-DED4ADE8E2DB</gtr:id><gtr:title>One remarkable molecule: filaggrin.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0f6cee6e470ed40c446ff0e9f5a3149"><gtr:id>d0f6cee6e470ed40c446ff0e9f5a3149</gtr:id><gtr:otherNames>Brown SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>pm_15081_21_22158554</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4EDC67B0-7207-4731-803E-9CA05121E708</gtr:id><gtr:title>Specific filaggrin mutations cause ichthyosis vulgaris and are significantly associated with atopic dermatitis in Japan.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c53890064db5facaa5d83b374e28167"><gtr:id>2c53890064db5facaa5d83b374e28167</gtr:id><gtr:otherNames>Nomura T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>226C2171AA6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F3BB4B4-D1D5-40BD-B56D-097CE696A2D4</gtr:id><gtr:title>South African amaXhosa patients with atopic dermatitis have decreased levels of filaggrin breakdown products but no loss-of-function mutations in filaggrin.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/192107c57f697372a15ce1d68fd101e3"><gtr:id>192107c57f697372a15ce1d68fd101e3</gtr:id><gtr:otherNames>Thawer-Esmail F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>56e0681d6e8682.03337737</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DFF38977-1BF7-4B44-A2D1-18FDD22B7F7C</gtr:id><gtr:title>Unique mutations in the filaggrin gene in Japanese patients with ichthyosis vulgaris and atopic dermatitis.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c53890064db5facaa5d83b374e28167"><gtr:id>2c53890064db5facaa5d83b374e28167</gtr:id><gtr:otherNames>Nomura T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>33B072AF6D3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF2382B4-3E19-46D2-8F63-62AC0DB9BF62</gtr:id><gtr:title>Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55b03925a89ecafca13d607e205db131"><gtr:id>55b03925a89ecafca13d607e205db131</gtr:id><gtr:otherNames>Sandilands A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>D2466B71243</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B22CB07-4E1B-43D3-8C7D-2CB64545D610</gtr:id><gtr:title>Genome-wide comparative analysis of atopic dermatitis and psoriasis gives insight into opposing genetic mechanisms.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0ccf974f83ca48e2ea50acd96b3f211"><gtr:id>d0ccf974f83ca48e2ea50acd96b3f211</gtr:id><gtr:otherNames>Baurecht H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>56e068204539c2.71788835</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5DC39872-5201-4875-A6C6-F5710C8DEA8E</gtr:id><gtr:title>Novel molecular therapies for heritable skin disorders.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68e09d03badf2c6a33c71d30993b5c56"><gtr:id>68e09d03badf2c6a33c71d30993b5c56</gtr:id><gtr:otherNames>Uitto J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>pm_15081_21_22158553</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>559B264F-7294-4B62-815F-59F14C1AFBA0</gtr:id><gtr:title>Filaggrin genotype in ichthyosis vulgaris predicts abnormalities in epidermal structure and function.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ab370a86694fb9ee878ce474bfb70c8"><gtr:id>6ab370a86694fb9ee878ce474bfb70c8</gtr:id><gtr:otherNames>Gruber R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn><gtr:outcomeId>Sy9LHUGdutJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EAFCAF52-4EB5-43C4-B60A-F55D2A2C3EC4</gtr:id><gtr:title>Peanut allergy: effect of environmental peanut exposure in children with filaggrin loss-of-function mutations.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d7479da87c295dbb6a12108c74ccf59"><gtr:id>6d7479da87c295dbb6a12108c74ccf59</gtr:id><gtr:otherNames>Brough HA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>56e0681faad140.01959289</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B80FA66-7F21-4924-B3CD-8B4A98060ABE</gtr:id><gtr:title>Wide spectrum of filaggrin-null mutations in atopic dermatitis highlights differences between Singaporean Chinese and European populations.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36e6bd83dfd373c441dfe6211f736a6c"><gtr:id>36e6bd83dfd373c441dfe6211f736a6c</gtr:id><gtr:otherNames>Chen H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>degUaThQN2N</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66C95575-566B-4F8B-9A0D-070B3D574320</gtr:id><gtr:title>Filaggrin loss-of-function mutations are associated with enhanced expression of IL-1 cytokines in the stratum corneum of patients with atopic dermatitis and in a murine model of filaggrin deficiency.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/82ffd45ccfb927492ab06f9d599920d6"><gtr:id>82ffd45ccfb927492ab06f9d599920d6</gtr:id><gtr:otherNames>Kezic S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>pm_15081_21_22322004</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5914FA17-922F-4340-9793-9EB1064D9D1C</gtr:id><gtr:title>Null mutations in the filaggrin gene (FLG) determine major susceptibility to early-onset atopic dermatitis that persists into adulthood.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9fb20aaf7b44ac5d6609c988fc7229de"><gtr:id>9fb20aaf7b44ac5d6609c988fc7229de</gtr:id><gtr:otherNames>Barker JN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>8023485D96C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCFFB7B1-1651-4983-9C3E-D830C3B76AF8</gtr:id><gtr:title>Filaggrin failure - from ichthyosis vulgaris to atopic eczema and beyond.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a06ac4c15fa5ab9d9f15bd95c259659"><gtr:id>1a06ac4c15fa5ab9d9f15bd95c259659</gtr:id><gtr:otherNames>McLean WH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>58ca50afbe7301.08003968</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DCD863D2-44DF-4C2C-A2EC-851417605B3D</gtr:id><gtr:title>The burden of disease associated with filaggrin mutations: a population-based, longitudinal birth cohort study.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32fe4ceebc1ed31dd64b02d54fe50612"><gtr:id>32fe4ceebc1ed31dd64b02d54fe50612</gtr:id><gtr:otherNames>Henderson J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>D22D84E36D8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A06F2BB4-8612-4A63-BEE3-E36D6361BA79</gtr:id><gtr:title>The allergy gene: how a mutation in a skin protein revealed a link between eczema and asthma.</gtr:title><gtr:parentPublicationTitle>F1000 medicine reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a06ac4c15fa5ab9d9f15bd95c259659"><gtr:id>1a06ac4c15fa5ab9d9f15bd95c259659</gtr:id><gtr:otherNames>McLean WH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1757-5931</gtr:issn><gtr:outcomeId>dag9Q1jzDWN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1305439A-5CF1-4777-BE00-7E5688BBDBA3</gtr:id><gtr:title>Deletion of Late Cornified Envelope 3B and 3C genes is not associated with atopic dermatitis.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/885b6a99bf5ff831b9468135e5a725d0"><gtr:id>885b6a99bf5ff831b9468135e5a725d0</gtr:id><gtr:otherNames>Bergboer JG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>kHFVvoV98Tx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F637923C-5095-4985-90CD-D52A8C972B5F</gtr:id><gtr:title>Copy-number mutations on chromosome 17q24.2-q24.3 in congenital generalized hypertrichosis terminalis with or without gingival hyperplasia.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5836679f6d774fb6e9c28abda8452530"><gtr:id>5836679f6d774fb6e9c28abda8452530</gtr:id><gtr:otherNames>Sun M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>C9793EA9DC6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B33DD6CC-07AF-4BA1-93FA-3D73884CC3C8</gtr:id><gtr:title>Filaggrin gene mutation associations with peanut allergy persist despite variations in peanut allergy diagnostic criteria or asthma status.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6bc8e4ea387c77583399904c4abbd65b"><gtr:id>6bc8e4ea387c77583399904c4abbd65b</gtr:id><gtr:otherNames>Asai Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>pm_15081_21_23684069</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9CE68905-FBA3-4E80-ABE2-5C605C71A39F</gtr:id><gtr:title>Identification of a novel family of laminin N-terminal alternate splice isoforms: structural and functional characterization.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c947d5a0da7889a950b3f48006a1b53d"><gtr:id>c947d5a0da7889a950b3f48006a1b53d</gtr:id><gtr:otherNames>Hamill KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>293DDBCC7E3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>862D198E-65A7-4907-9017-C221EABAE3B6</gtr:id><gtr:title>Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita.</gtr:title><gtr:parentPublicationTitle>Journal of dermatological science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33c495952b4fc5fe6774d1b49df82ab2"><gtr:id>33c495952b4fc5fe6774d1b49df82ab2</gtr:id><gtr:otherNames>Leachman SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0923-1811</gtr:issn><gtr:outcomeId>72EAC29FD17</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3BD2937-B473-432B-ABDE-69DB69040BEB</gtr:id><gtr:title>A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/46d831ce8ae2662e3d42bdf88c194555"><gtr:id>46d831ce8ae2662e3d42bdf88c194555</gtr:id><gtr:otherNames>Genetic Analysis of Psoriasis Consortium &amp; the Wellcome Trust Case Control Consortium 2</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>Tfr7DJArCmZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AFE94FEF-06D2-4266-A9A3-CFE366DBE0BA</gtr:id><gtr:title>A new filaggrin gene mutation in a Korean patient with ichthyosis vulgaris.</gtr:title><gtr:parentPublicationTitle>European journal of dermatology : EJD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b4f3086ec91b7078c1db014dd69e2f1"><gtr:id>8b4f3086ec91b7078c1db014dd69e2f1</gtr:id><gtr:otherNames>Ohguchi Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1167-1122</gtr:issn><gtr:outcomeId>56e0681f2d0d12.12098900</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BFED5D1-84CF-46F8-8403-4C72FD1D87D4</gtr:id><gtr:title>Filaggrin mutations associated with skin and allergic diseases.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2955fa70390b4f5735bb7b43c1a22eae"><gtr:id>2955fa70390b4f5735bb7b43c1a22eae</gtr:id><gtr:otherNames>Irvine AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>hBNxZ8ofPri</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1F7FF39-B8DF-4F84-92FC-9EFEE0BBE3AA</gtr:id><gtr:title>Development of therapeutic siRNAs for pachyonychia congenita.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8e6d42aca09807f5cdb5643059d86ab"><gtr:id>b8e6d42aca09807f5cdb5643059d86ab</gtr:id><gtr:otherNames>Smith FJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>6A6020F6959</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC84611F-DE81-456B-9139-1D977717D178</gtr:id><gtr:title>Filaggrin in the frontline: role in skin barrier function and disease.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55b03925a89ecafca13d607e205db131"><gtr:id>55b03925a89ecafca13d607e205db131</gtr:id><gtr:otherNames>Sandilands A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>4711547D075</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5CF4751D-FF42-4108-A009-6DBD7BB3D4F1</gtr:id><gtr:title>High-density genotyping study identifies four new susceptibility loci for atopic dermatitis.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/634fc019719cff5c15842e6960bd2bd7"><gtr:id>634fc019719cff5c15842e6960bd2bd7</gtr:id><gtr:otherNames>Ellinghaus D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>pm_15081_21_23727859</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B241203-747D-47A1-896C-29DA7D6F472D</gtr:id><gtr:title>Japanese-specific filaggrin gene mutations in Japanese patients suffering from atopic eczema and asthma.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0310e3d93fa77659e217c060830f28d3"><gtr:id>0310e3d93fa77659e217c060830f28d3</gtr:id><gtr:otherNames>Osawa R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>WpKf2NLBNtW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CB69A25-6B0E-4B25-8F4C-EED133B7A342</gtr:id><gtr:title>Raman profiles of the stratum corneum define 3 filaggrin genotype-determined atopic dermatitis endophenotypes.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b180857fbe2eda4a0cdbbb8a2c253b2"><gtr:id>3b180857fbe2eda4a0cdbbb8a2c253b2</gtr:id><gtr:otherNames>O'Regan GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>qMDHRgByZFq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10F9A2E5-CC66-48B8-A4D5-15E8F686EBCF</gtr:id><gtr:title>In vivo gene silencing following non-invasive siRNA delivery into the skin using a novel topical formulation.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d41aaa72233ee1310e41f89d5608b9b2"><gtr:id>d41aaa72233ee1310e41f89d5608b9b2</gtr:id><gtr:otherNames>Hegde V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn><gtr:outcomeId>doi_55f9859850a45061</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CCFDC339-82E2-4CE2-B895-D6CDEA518DAC</gtr:id><gtr:title>Too Much, Too Little or Just Enough: A Goldilocks Effect for IL-13 and Skin Barrier Regulation?</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6c672f701d0cce2018591c75b1b388f"><gtr:id>f6c672f701d0cce2018591c75b1b388f</gtr:id><gtr:otherNames>Strid J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>58ca50afe7ad99.06942586</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B861CB4-5339-4D8F-B89F-8EBCC957B9F6</gtr:id><gtr:title>SiRNA-mediated selective inhibition of mutant keratin mRNAs responsible for the skin disorder pachyonychia congenita.</gtr:title><gtr:parentPublicationTitle>Annals of the New York Academy of Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb2b3892d790bb4dcf1068f75965dad2"><gtr:id>bb2b3892d790bb4dcf1068f75965dad2</gtr:id><gtr:otherNames>Hickerson RP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0077-8923</gtr:issn><gtr:outcomeId>9B5673555F7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D4BCC78-AE09-43F2-A964-73008D663A80</gtr:id><gtr:title>Eczema genetics: current state of knowledge and future goals.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0f6cee6e470ed40c446ff0e9f5a3149"><gtr:id>d0f6cee6e470ed40c446ff0e9f5a3149</gtr:id><gtr:otherNames>Brown SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>5C010B8329D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C169391-C280-470B-AD46-FB9EE1CB10EF</gtr:id><gtr:title>Loss-of-Function Mutations in the Gene Encoding Filaggrin Are Not Strongly Associated with Chronic Actinic Dermatitis.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b3af0d00c2093a21f07c697e3a07bb8a"><gtr:id>b3af0d00c2093a21f07c697e3a07bb8a</gtr:id><gtr:otherNames>Harkins CP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>56e06820b560a7.11492753</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8AFE98BA-1221-4914-8A6C-D5EE5279CBE5</gtr:id><gtr:title>Single-nucleotide-specific siRNA targeting in a dominant-negative skin model.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb2b3892d790bb4dcf1068f75965dad2"><gtr:id>bb2b3892d790bb4dcf1068f75965dad2</gtr:id><gtr:otherNames>Hickerson RP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>336DB452CCB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14F918CF-ADD1-4CBB-822B-627A3174175F</gtr:id><gtr:title>Atopic dermatitis and disease severity are the main risk factors for food sensitization in exclusively breastfed infants.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/968b8e238b0bc7f8c4a80a997cbc89a8"><gtr:id>968b8e238b0bc7f8c4a80a997cbc89a8</gtr:id><gtr:otherNames>Flohr C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>pm_15081_21_23867897</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1CBAE4DA-98AE-4809-BED2-EE71A81E0D59</gtr:id><gtr:title>Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and inflammatory bowel disease, and a decreased risk for type 1 diabetes.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f0e930067633bec9e79ed363489cf3a7"><gtr:id>f0e930067633bec9e79ed363489cf3a7</gtr:id><gtr:otherNames>Schmitt J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>56e0682185a583.66143109</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12E7AB28-3606-4BD4-A91D-3AF6C883A607</gtr:id><gtr:title>Reliability and validity of genotyping filaggrin null mutations.</gtr:title><gtr:parentPublicationTitle>Journal of dermatological science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b073531150745dba9239b8fa314cb637"><gtr:id>b073531150745dba9239b8fa314cb637</gtr:id><gtr:otherNames>Margolis DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0923-1811</gtr:issn><gtr:outcomeId>pm_15081_21_23274172</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62DE3453-1CC5-4D7E-84DB-337B2B4ED080</gtr:id><gtr:title>Filaggrin null mutations and childhood atopic eczema: a population-based case-control study.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0f6cee6e470ed40c446ff0e9f5a3149"><gtr:id>d0f6cee6e470ed40c446ff0e9f5a3149</gtr:id><gtr:otherNames>Brown SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>7415221D5AF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ACBCFC05-F2DA-421E-83FE-9C8BD86A47E8</gtr:id><gtr:title>Filaggrin loss-of-function mutations are associated with early-onset eczema, eczema severity and transepidermal water loss at 3 months of age.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/968b8e238b0bc7f8c4a80a997cbc89a8"><gtr:id>968b8e238b0bc7f8c4a80a997cbc89a8</gtr:id><gtr:otherNames>Flohr C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>jdczKGBAWBz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2EE5CC4D-9CC7-495C-9493-5EBC1D3DE274</gtr:id><gtr:title>Keratin 7 promoter selectively targets transgene expression to normal and neoplastic pancreatic ductal cells in vitro and in vivo.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a245d0cc5cdb49c2e759e4560a126911"><gtr:id>a245d0cc5cdb49c2e759e4560a126911</gtr:id><gtr:otherNames>Pujal J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn><gtr:outcomeId>2D552692289</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A3F2F0E-DAF6-40C2-8B7F-334F9007763A</gtr:id><gtr:title>Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd8ed65877cadf6fedde93c7324be7fe"><gtr:id>dd8ed65877cadf6fedde93c7324be7fe</gtr:id><gtr:otherNames>Simpson EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>56e0681f571324.15608748</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A487930-481F-46D5-B5C8-AC61E3B19ED4</gtr:id><gtr:title>Keratin K6c mutations cause focal palmoplantar keratoderma.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee30dd370782ce25fab3dc90f4cebcf9"><gtr:id>ee30dd370782ce25fab3dc90f4cebcf9</gtr:id><gtr:otherNames>Wilson NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>304CFC55BC8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D60A2536-24FB-4594-AF4C-5FC31EAE1DEB</gtr:id><gtr:title>Focal palmoplantar keratoderma caused by an autosomal dominant inherited mutation in the desmoglein 1 gene.</gtr:title><gtr:parentPublicationTitle>Dermatology (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31cae29bf409518c87adf2a0ad001547"><gtr:id>31cae29bf409518c87adf2a0ad001547</gtr:id><gtr:otherNames>Milingou M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1018-8665</gtr:issn><gtr:outcomeId>39DD81A40E3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8621E7AB-B9A7-4D6C-90B9-B1AAA04765C9</gtr:id><gtr:title>Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8e6d42aca09807f5cdb5643059d86ab"><gtr:id>b8e6d42aca09807f5cdb5643059d86ab</gtr:id><gtr:otherNames>Smith FJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>E8682990EF5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C048E34-3090-49B6-8E9A-356EAC124211</gtr:id><gtr:title>A heterozygous frameshift mutation in the V1 domain of keratin 5 in a family with Dowling-Degos disease.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d59f85b8e3d5471bf73b246942c201b"><gtr:id>7d59f85b8e3d5471bf73b246942c201b</gtr:id><gtr:otherNames>Liao H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>40D36021D42</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96D94B0E-95EA-4D5E-A674-CE39BA346EE7</gtr:id><gtr:title>Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54a4658ef858b411d66e115aaf52aba8"><gtr:id>54a4658ef858b411d66e115aaf52aba8</gtr:id><gtr:otherNames>Tsoi LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>pm_15081_21_23143594</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38ECD176-2EA3-46B0-B7E4-3981769C9ECC</gtr:id><gtr:title>Analysis of the individual and aggregate genetic contributions of previously identified serine peptidase inhibitor Kazal type 5 (SPINK5), kallikrein-related peptidase 7 (KLK7), and filaggrin (FLG) polymorphisms to eczema risk.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9667662b8ddb576cb53a1eba36b681b"><gtr:id>a9667662b8ddb576cb53a1eba36b681b</gtr:id><gtr:otherNames>Weidinger S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>512A02EC342</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87118D3D-C90A-4433-BEC7-709AC37224BC</gtr:id><gtr:title>Filaggrin null mutations are associated with increased asthma severity in children and young adults.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e58394649297bcf1ab285b4dfd88ec77"><gtr:id>e58394649297bcf1ab285b4dfd88ec77</gtr:id><gtr:otherNames>Palmer CN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>7EA9B37E76F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E24839F-2D0B-44AF-B302-DF55E6BCF5A5</gtr:id><gtr:title>Exacerbation of X-linked ichthyosis phenotype in a female by inheritance of filaggrin and steroid sulfatase mutations.</gtr:title><gtr:parentPublicationTitle>Journal of dermatological science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5c38f0be36b156d8dcf6a0917fe6e75"><gtr:id>a5c38f0be36b156d8dcf6a0917fe6e75</gtr:id><gtr:otherNames>Ramesh R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0923-1811</gtr:issn><gtr:outcomeId>rkM28FuuQz3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C31D0F2B-5DAB-4960-9071-6A0EF8466377</gtr:id><gtr:title>Steatocystoma multiplex, oligodontia and partial persistent primary dentition associated with a novel keratin 17 mutation.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/38ea6079b76e4bf085880c7c9858d783"><gtr:id>38ea6079b76e4bf085880c7c9858d783</gtr:id><gtr:otherNames>Gass JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>F8CD14B053F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3B4E1EBB-58AB-463A-8057-6CEE5A75956F</gtr:id><gtr:title>Filaggrin mutations in the onset of eczema, sensitization, asthma, hay fever and the interaction with cat exposure.</gtr:title><gtr:parentPublicationTitle>Allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/339732df5d0083a177e7844122f8d726"><gtr:id>339732df5d0083a177e7844122f8d726</gtr:id><gtr:otherNames>Schuttelaar ML</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn><gtr:outcomeId>B7BFD964485</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E3819B3-83C5-4A13-A78C-D90FFF12C138</gtr:id><gtr:title>Novel filaggrin mutation but no other loss-of-function variants found in Ethiopian patients with atopic dermatitis.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9c3ae4ec3096099f6780e1c152e520c"><gtr:id>d9c3ae4ec3096099f6780e1c152e520c</gtr:id><gtr:otherNames>Winge MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>W2xr31SDfSr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0C3F806-442A-432F-98D2-078E72B3D36D</gtr:id><gtr:title>Heterozygous null alleles in filaggrin contribute to clinical dry skin in young adults and the elderly.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/854401488c20a128c54172ea66e7d9b4"><gtr:id>854401488c20a128c54172ea66e7d9b4</gtr:id><gtr:otherNames>Sergeant A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>D3E5A55CE48</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49E6ABBD-9743-42B5-A64C-0ADCBA8708C6</gtr:id><gtr:title>Unique and recurrent mutations in the filaggrin gene in Singaporean Chinese patients with ichthyosis vulgaris.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36e6bd83dfd373c441dfe6211f736a6c"><gtr:id>36e6bd83dfd373c441dfe6211f736a6c</gtr:id><gtr:otherNames>Chen H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>5A74044873E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A8461D5-1F0B-4DB6-A10D-A176844FA473</gtr:id><gtr:title>First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33c495952b4fc5fe6774d1b49df82ab2"><gtr:id>33c495952b4fc5fe6774d1b49df82ab2</gtr:id><gtr:otherNames>Leachman SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>4A6D182AA8D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D618269B-E75C-489A-84FB-01DF906EE50F</gtr:id><gtr:title>Mutations in the SASPase gene (ASPRV1) are not associated with atopic eczema or clinically dry skin.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55b03925a89ecafca13d607e205db131"><gtr:id>55b03925a89ecafca13d607e205db131</gtr:id><gtr:otherNames>Sandilands A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>pm_15081_21_22318384</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2CC3505-F551-4A49-8DF1-0BBFE29CE788</gtr:id><gtr:title>A spectrum of mutations in keratins K6a, K16 and K17 causing pachyonychia congenita.</gtr:title><gtr:parentPublicationTitle>Journal of dermatological science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d59f85b8e3d5471bf73b246942c201b"><gtr:id>7d59f85b8e3d5471bf73b246942c201b</gtr:id><gtr:otherNames>Liao H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0923-1811</gtr:issn><gtr:outcomeId>7298E19CC95</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF770B71-8E64-4678-94AF-C61F2C76A128</gtr:id><gtr:title>Association between domestic water hardness, chlorine, and atopic dermatitis risk in early life: A&amp;nbsp;population-based cross-sectional study.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c483b619c701caf379f39b4e5fdd40ae"><gtr:id>c483b619c701caf379f39b4e5fdd40ae</gtr:id><gtr:otherNames>Perkin MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>58ca50aebc6308.63058340</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FDD45F9C-1E82-4FC3-A879-72D570492180</gtr:id><gtr:title>Skin barrier function in healthy subjects and patients with atopic dermatitis in relation to filaggrin loss-of-function mutations.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f60cd239b8411ddc5fde247de82001e2"><gtr:id>f60cd239b8411ddc5fde247de82001e2</gtr:id><gtr:otherNames>Jakasa I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>ULBhi8bnrVQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1452F975-4CCD-4BD0-B0D4-404698AD4E21</gtr:id><gtr:title>Siglec-E promotes ?2-integrin-dependent NADPH oxidase activation to suppress neutrophil recruitment to the lung.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5877cc27b23379ab70ae407e8deaf272"><gtr:id>5877cc27b23379ab70ae407e8deaf272</gtr:id><gtr:otherNames>McMillan SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>54624351b17f29.62999113</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7842FCAC-C2C6-400E-A387-153CD88E75D6</gtr:id><gtr:title>Severe dermatitis, multiple allergies, and metabolic wasting syndrome caused by a novel mutation in the N-terminal plakin domain of desmoplakin.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de448266df10355a46b2241955bd4724"><gtr:id>de448266df10355a46b2241955bd4724</gtr:id><gtr:otherNames>McAleer MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>56e068215fdf33.58320385</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC99D8F5-1962-40CC-8CDA-D778BA8781BA</gtr:id><gtr:title>Filaggrin mutations are genetic modifying factors exacerbating X-linked ichthyosis.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d59f85b8e3d5471bf73b246942c201b"><gtr:id>7d59f85b8e3d5471bf73b246942c201b</gtr:id><gtr:otherNames>Liao H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>28AC1CFFFFB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F9D78A1-C5E3-420A-819C-D403103FE66F</gtr:id><gtr:title>Intragenic copy number variation within filaggrin contributes to the risk of atopic dermatitis with a dose-dependent effect.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0f6cee6e470ed40c446ff0e9f5a3149"><gtr:id>d0f6cee6e470ed40c446ff0e9f5a3149</gtr:id><gtr:otherNames>Brown SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>Q3m3CEpXktH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91DD7887-0293-4E74-B01C-28437F9C1F15</gtr:id><gtr:title>Skin barrier dysfunction measured by transepidermal water loss at 2 days and 2 months predates and predicts atopic dermatitis at 1 year.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/22324572cb1c75685956e986c0c63840"><gtr:id>22324572cb1c75685956e986c0c63840</gtr:id><gtr:otherNames>Kelleher M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>56e06820883084.79078766</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E477FE20-9B11-4AF9-9586-BE978FFF23DD</gtr:id><gtr:title>Filaggrin mutations are associated with recurrent skin infection in Singaporean Chinese patients with atopic dermatitis.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc02f5f3249cd7a054de11f87548381a"><gtr:id>dc02f5f3249cd7a054de11f87548381a</gtr:id><gtr:otherNames>Cai SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>Jv3nrVRuvmB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD05FE27-05A8-4238-AF52-D47638812FA0</gtr:id><gtr:title>A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays.</gtr:title><gtr:parentPublicationTitle>PLoS biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed63a9d2ecf893de047b88ad09ec4f4a"><gtr:id>ed63a9d2ecf893de047b88ad09ec4f4a</gtr:id><gtr:otherNames>McElroy SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1544-9173</gtr:issn><gtr:outcomeId>pm_15081_21_23824517</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B899A197-4B79-468C-8E8D-B842590630A8</gtr:id><gtr:title>Filaggrin genotype does not determine the skin's threshold to UV-induced erythema.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f42e6d73e7e080b309807b4bce749d6b"><gtr:id>f42e6d73e7e080b309807b4bce749d6b</gtr:id><gtr:otherNames>Forbes D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>56e0682278d635.09433042</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17AAE6AA-3C55-474B-94B2-CEA528949D1E</gtr:id><gtr:title>Filaggrin in atopic dermatitis.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b180857fbe2eda4a0cdbbb8a2c253b2"><gtr:id>3b180857fbe2eda4a0cdbbb8a2c253b2</gtr:id><gtr:otherNames>O'Regan GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>53648240EC8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40594552-627A-482D-8A7C-D512871A4F9A</gtr:id><gtr:title>Filaggrin loss-of-function mutations and atopic dermatitis as risk factors for hand eczema in apprentice nurses: part II of a prospective cohort study.</gtr:title><gtr:parentPublicationTitle>Contact dermatitis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6eac5775e4b7c1daea755c6a16a68ab"><gtr:id>f6eac5775e4b7c1daea755c6a16a68ab</gtr:id><gtr:otherNames>Visser MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0105-1873</gtr:issn><gtr:outcomeId>56e0681d96ee96.36806124</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15551255-C240-4B67-8FC3-63CB74D83E09</gtr:id><gtr:title>Filaggrin breakdown products determine corneocyte conformation in patients with atopic dermatitis.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc5889dbb3ec7e039ab0cc28012c7ce6"><gtr:id>dc5889dbb3ec7e039ab0cc28012c7ce6</gtr:id><gtr:otherNames>Riethmuller C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>56e0682128d103.13964982</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD31BD21-EBE8-4581-BF6D-BEEFEFE220A7</gtr:id><gtr:title>Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9667662b8ddb576cb53a1eba36b681b"><gtr:id>a9667662b8ddb576cb53a1eba36b681b</gtr:id><gtr:otherNames>Weidinger S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>8617B36B723</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EEB8EF98-B17D-4431-95B9-184464B10950</gtr:id><gtr:title>Analysis of Taiwanese ichthyosis vulgaris families further demonstrates differences in FLG mutations between European and Asian populations.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a67b588802f4c7d2ffac350a6e9ea5c0"><gtr:id>a67b588802f4c7d2ffac350a6e9ea5c0</gtr:id><gtr:otherNames>Hsu CK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>FAEA270D593</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A920B447-762B-4AD9-9BEE-6DEDB89CD1CC</gtr:id><gtr:title>Filaggrin loss-of-function variants are associated with atopic comorbidity in pediatric inflammatory bowel disease.</gtr:title><gtr:parentPublicationTitle>Inflammatory bowel diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f444492accbb6a473246d6fe44c8a127"><gtr:id>f444492accbb6a473246d6fe44c8a127</gtr:id><gtr:otherNames>Van Limbergen J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1078-0998</gtr:issn><gtr:outcomeId>175A808EA89</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C05E93EF-28EB-44CD-B10F-6EE19CED816B</gtr:id><gtr:title>Filaggrin haploinsufficiency is highly penetrant and is associated with increased severity of eczema: further delineation of the skin phenotype in a prospective epidemiological study of 792 school children.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0f6cee6e470ed40c446ff0e9f5a3149"><gtr:id>d0f6cee6e470ed40c446ff0e9f5a3149</gtr:id><gtr:otherNames>Brown SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>C0C78B79E9A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1360251B-BFCE-4F8F-BE53-B0C41904E465</gtr:id><gtr:title>Loss-of-function mutations of an inhibitory upstream ORF in the human hairless transcript cause Marie Unna hereditary hypotrichosis.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bef9b0dd722a3f29d45b5ea184c9295"><gtr:id>5bef9b0dd722a3f29d45b5ea184c9295</gtr:id><gtr:otherNames>Wen Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>B015CD30A11</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F153EAE8-7A08-4ECB-8F50-B447A623B57A</gtr:id><gtr:title>Mutation in DSG1 causing autosomal dominant striate palmoplantar keratoderma.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9006945c5078d06adbe80fa66a7fcc71"><gtr:id>9006945c5078d06adbe80fa66a7fcc71</gtr:id><gtr:otherNames>Zamiri M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>3F680354DF7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DCFDF0E9-A696-4524-929F-5A5CC63FC2F8</gtr:id><gtr:title>Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e58394649297bcf1ab285b4dfd88ec77"><gtr:id>e58394649297bcf1ab285b4dfd88ec77</gtr:id><gtr:otherNames>Palmer CN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>3021132A059</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9622069-93CF-4DA4-B9B4-48F92F1A66DA</gtr:id><gtr:title>Filaggrin null alleles are not associated with psoriasis.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/673680106ade3187f249d2a683028495"><gtr:id>673680106ade3187f249d2a683028495</gtr:id><gtr:otherNames>Zhao Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>75834820E2B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C8D1CFB-DE3B-4626-831A-83958FEB0CBA</gtr:id><gtr:title>Prevalent and rare mutations in the gene encoding filaggrin cause ichthyosis vulgaris and predispose individuals to atopic dermatitis.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55b03925a89ecafca13d607e205db131"><gtr:id>55b03925a89ecafca13d607e205db131</gtr:id><gtr:otherNames>Sandilands A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>C35B9D42A93</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4410339A-226A-49BC-ACE0-8BB7CF93BA41</gtr:id><gtr:title>Chromosome 11q13.5 variant associated with childhood eczema: an effect supplementary to filaggrin mutations.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b180857fbe2eda4a0cdbbb8a2c253b2"><gtr:id>3b180857fbe2eda4a0cdbbb8a2c253b2</gtr:id><gtr:otherNames>O'Regan GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>Gcg74UhezGb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70F9EEB9-04E2-45DC-951A-C630FFC81E1D</gtr:id><gtr:title>Broken bricks and cracked mortar - epidermal diseases resulting from genetic abnormalities</gtr:title><gtr:parentPublicationTitle>Drug Discovery Today: Disease Mechanisms</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d27e98166c20bb334efb8e475cb7e1da"><gtr:id>d27e98166c20bb334efb8e475cb7e1da</gtr:id><gtr:otherNames>Lane E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:outcomeId>56FAD46F994</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2D06ED6-53C1-476A-A1A8-2685BE81A14D</gtr:id><gtr:title>Ichthyosis vulgaris: novel FLG mutations in the German population and high presence of CD1a+ cells in the epidermis of the atopic subgroup.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8165cc6912441777a23e192eb12e29dc"><gtr:id>8165cc6912441777a23e192eb12e29dc</gtr:id><gtr:otherNames>Oji V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>70BE06D4019</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3F77720-E692-4D5F-BE23-3905846E709D</gtr:id><gtr:title>De novo occurrence of the filaggrin mutation p.R501X with prevalent mutation c.3321delA in a Japanese family with ichthyosis vulgaris complicated by atopic dermatitis.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cfb67cf7809da155b2c17864921dc35e"><gtr:id>cfb67cf7809da155b2c17864921dc35e</gtr:id><gtr:otherNames>Hamada T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>AF7D2873355</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBAFE367-AFA0-42FD-971F-9C665E4FFF4F</gtr:id><gtr:title>Loss-of-function mutations in the filaggrin gene lead to reduced level of natural moisturizing factor in the stratum corneum.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/82ffd45ccfb927492ab06f9d599920d6"><gtr:id>82ffd45ccfb927492ab06f9d599920d6</gtr:id><gtr:otherNames>Kezic S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>DE0D1B25597</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7154B8A7-FB9D-4A61-9679-E4CFDCD687D3</gtr:id><gtr:title>Filaggrin null mutations are associated with increased asthma exacerbations in children and young adults.</gtr:title><gtr:parentPublicationTitle>Allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5d7806bf13ff88b4f2a6100e7c30c91"><gtr:id>d5d7806bf13ff88b4f2a6100e7c30c91</gtr:id><gtr:otherNames>Basu K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn><gtr:outcomeId>DE5F0FE1455</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA17EA23-77C1-4B52-82ED-2518818D31EE</gtr:id><gtr:title>Skin barrier impairment at birth predicts food allergy at 2 years of age.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db534d37e38be0fed88bcf7d1e1dc72b"><gtr:id>db534d37e38be0fed88bcf7d1e1dc72b</gtr:id><gtr:otherNames>Kelleher MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>58ca50ae50f0b7.12155046</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7320B826-9D07-4D4B-9187-44B81FD86E46</gtr:id><gtr:title>Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea922bc4db1d3ac9a99cc64f7d1d0eea"><gtr:id>ea922bc4db1d3ac9a99cc64f7d1d0eea</gtr:id><gtr:otherNames>Paternoster L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>56e06821f2ef57.25994446</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C382F70-5369-4C84-8F2F-BFAB059171E3</gtr:id><gtr:title>Prevalent and rare mutations in the gene encoding filaggrin in Japanese patients with ichthyosis vulgaris and atopic dermatitis.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c53890064db5facaa5d83b374e28167"><gtr:id>2c53890064db5facaa5d83b374e28167</gtr:id><gtr:otherNames>Nomura T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>3E6941C3AE2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DFF2ED72-EC8C-4785-ACE2-691A82D997CB</gtr:id><gtr:title>Statins downregulate K6a promoter activity: a possible therapeutic avenue for pachyonychia congenita.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/673680106ade3187f249d2a683028495"><gtr:id>673680106ade3187f249d2a683028495</gtr:id><gtr:otherNames>Zhao Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>BBPmFbTkbGX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B8EE75E-9685-4BA6-AA14-FB6B3362A84A</gtr:id><gtr:title>A homozygous frameshift mutation in the mouse Flg gene facilitates enhanced percutaneous allergen priming.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/295172cf06eb3e4362654ec26ea2b873"><gtr:id>295172cf06eb3e4362654ec26ea2b873</gtr:id><gtr:otherNames>Fallon PG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>7446D2D74B1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A5B3CA8-451F-4F17-A5C6-10F59CA8ECC6</gtr:id><gtr:title>Filaggrin mutations, atopic eczema, hay fever, and asthma in children.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9667662b8ddb576cb53a1eba36b681b"><gtr:id>a9667662b8ddb576cb53a1eba36b681b</gtr:id><gtr:otherNames>Weidinger S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>07F44845580</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD6C154A-E422-46D0-A57F-B326A1C18174</gtr:id><gtr:title>Carrier status for the common R501X and 2282del4 filaggrin mutations is not associated with hearing phenotypes in 5,377 children from the ALSPAC cohort.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc83b94d1f800e6c596d0df5a7553aa2"><gtr:id>cc83b94d1f800e6c596d0df5a7553aa2</gtr:id><gtr:otherNames>Rodriguez S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>2055320A6B0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>995B49C0-C7BD-445B-92AF-D85120354D00</gtr:id><gtr:title>Chromosome 11q13.5 variant: No association with atopic eczema in the Japanese population.</gtr:title><gtr:parentPublicationTitle>Journal of dermatological science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc305f04dfd672ca19dbeff985f7f115"><gtr:id>dc305f04dfd672ca19dbeff985f7f115</gtr:id><gtr:otherNames>Nomura Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0923-1811</gtr:issn><gtr:outcomeId>n5CfypZyW7B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3EAC8447-24B5-40EB-A3CB-67D1F7947325</gtr:id><gtr:title>Association of skin barrier genes within the PSORS4 locus is enriched in Singaporean Chinese with early-onset psoriasis.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36e6bd83dfd373c441dfe6211f736a6c"><gtr:id>36e6bd83dfd373c441dfe6211f736a6c</gtr:id><gtr:otherNames>Chen H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>EC1383009AC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69A6837D-1250-4E36-A0C3-FA2E23799132</gtr:id><gtr:title>Pachyonychia congenita type 2: abnormal dentition extending into adulthood.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9006945c5078d06adbe80fa66a7fcc71"><gtr:id>9006945c5078d06adbe80fa66a7fcc71</gtr:id><gtr:otherNames>Zamiri M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>0E5F2DBFD57</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6DA50E55-55B9-4C51-AD7E-BA61B532C8D4</gtr:id><gtr:title>Prevalent and low-frequency null mutations in the filaggrin gene are associated with early-onset and persistent atopic eczema.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0f6cee6e470ed40c446ff0e9f5a3149"><gtr:id>d0f6cee6e470ed40c446ff0e9f5a3149</gtr:id><gtr:otherNames>Brown SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>8F97D537B75</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20118220-ABF0-47F4-BC84-89965ABCDCCB</gtr:id><gtr:title>Atopic dermatitis increases the effect of exposure to peanut antigen in dust on peanut sensitization and likely peanut allergy.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d7479da87c295dbb6a12108c74ccf59"><gtr:id>6d7479da87c295dbb6a12108c74ccf59</gtr:id><gtr:otherNames>Brough HA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>56e0682012af96.38381946</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F2CB474-2627-4119-B8C3-CBCB555204AD</gtr:id><gtr:title>The Human Intermediate Filament Database: comprehensive information on a gene family involved in many human diseases.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/48e1af4ead1becf96d30e334bf450805"><gtr:id>48e1af4ead1becf96d30e334bf450805</gtr:id><gtr:otherNames>Szeverenyi I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>75A632137AA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE679B99-E640-47EE-B20B-A0D4096BA6D8</gtr:id><gtr:title>Compound heterozygotes for filaggrin gene mutations do not always show severe atopic dermatitis.</gtr:title><gtr:parentPublicationTitle>Journal of the European Academy of Dermatology and Venereology : JEADV</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9d19eb16788d83a3753d05b03fdcd86"><gtr:id>b9d19eb16788d83a3753d05b03fdcd86</gtr:id><gtr:otherNames>Sekiya A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0926-9959</gtr:issn><gtr:outcomeId>58ca50aeeaede5.96956812</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700314</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7EE9741E-CF94-420A-B0AB-A7811523CF2C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Skin</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>